Skip to main
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp has demonstrated a positive financial performance, highlighted by a 50 basis point year-over-year increase in gross margin and a substantial 280 basis point improvement in adjusted EBITDA margin. Sales in the Trauma & Deformity segment rose by 17.3% to $44.1 million, exceeding expectations, while the overall revenue growth outlook remains strong, with management projecting a revenue increase of over 12% in the coming years. Furthermore, the company is poised for continued margin improvement and enhanced cash flow, driven by new product introductions and increased distributor productivity.

Bears say

OrthoPediatrics Corp is facing a negative outlook due to slower-than-expected revenue growth, with KIDS revenue increasing only 12% in 3Q25 compared to 16% in 2Q25, indicating a decline in sales momentum. Additionally, the company lowered its FY25 revenue guidance to $233.5M-$234.5M, reflecting concerns about disappointing sales from recently acquired products and insufficient new product launches contributing to margin improvement. Furthermore, the deployment of product sets has decreased, falling to $4.1M in 3Q25, a 23% decline from the prior year's 3Q, which raises concerns regarding future cash flow sustainability and overall financial performance.

OrthoPediatrics (KIDS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, OrthoPediatrics (KIDS) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.